Arlocabtagene autoleucel：一种用于重度预治疗复发/难治性多发性骨髓瘤的靶向 GPRC5D CAR-T 细胞疗法
Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma.
97.0分
★★★★★
站内排序·非疗效
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
FRONTIER PAPERS
前沿论文 24
条件筛选 · 已选 4 项 · 共 24 条展开收起
多发性骨髓瘤中的双抗原靶向 T 细胞免疫治疗：规避肿瘤异质性和预防抗原逃逸
Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape.
84.3分
★★★★☆
站内排序·非疗效
多发性骨髓瘤的新型免疫靶点：生物学意义与治疗潜力
Novel immunotargets in multiple myeloma: biological relevance and therapeutic potential.
69.3分
★★★☆☆
站内排序·非疗效
探索 BCMA/GPRC5D 后的治疗格局：塞利尼索、硼替佐米与地塞米松在五重难治性多发性骨髓瘤序贯免疫治疗失败后的疗效——多中心分析
Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refrac
65.6分
★★★☆☆
站内排序·非疗效
靶向 BCMA 或 GPRC5D 的双特异性抗体在 CAR-T 细胞治疗后复发多发性骨髓瘤中高度有效
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy.
65.5分
★★★☆☆
站内排序·非疗效
ide-cel 早期复发后 BCMA 靶向双特异性抗体治疗结局不佳：一项法国真实世界研究
Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.
63.4分
★★★☆☆
站内排序·非疗效
整合免疫疗法治疗多发性骨髓瘤
Integrating Immune Therapies for the Treatment of Multiple Myeloma.
63.3分
★★★☆☆
站内排序·非疗效
通过单细胞测序鉴定复发/难治性多发性骨髓瘤中 BCMA CAR-T 治疗后复发的潜在耐药机制和治疗靶点
Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myelom
62.9分
★★★☆☆
站内排序·非疗效
多发性骨髓瘤 CAR-NK 细胞治疗的最新进展：细胞来源与靶抗原的综合综述
State of the Art of CAR-NK Cell Therapy in Multiple Myeloma: A Comprehensive Review of Cell Sources and Target Antigens.
58.1分
★★★☆☆
站内排序·非疗效
多发性骨髓瘤中的单特异性和双特异性嵌合抗原受体（CAR）T 细胞治疗：系统综述、荟萃分析与荟萃回归
Monospecific and Bispecific Chimeric Antigen Receptor (CAR) T-cell Therapy in Multiple Myeloma: A Systematic Review, Meta-analysis and Meta-regression
56.0分
★★★☆☆
站内排序·非疗效